An effective treatment method and composition for controlling a variety of diseases including disease in poultry are disclosed. The inventive concept set forth herein provides an improved long-lasting treatment having a positive latency effect for a broad variety of diseases that is easy to administer and cost effective. The disclosed method of treatment utilizes a compound derived from a lipopolysaccharide (LPS) of gram-negative bacteria. By administering the compound early in broiler life, disease prevention and treatment via immune modulation result. The treatment has a lasting effect throughout the entire broiler production period. The composition itself is a natural product and thus has no adverse environmental impact unlike known antibiotic regimens. By providing effective treatment during the stage of life where feed consumption is lowest by volume, costs to the producer are advantageously limited.

The present invention describes a method of inhibiting inflammatory response by using a lipopolysaccharide of Parabacteroides goldsteinii. The lipopolysaccharide of Parabacteroides goldsteinii can effectively inhibit the immune responses caused by pathogenic lipopolysaccharides in peripheral blood mononuclear cells, macrophages, and/or B cells, and then can be effectively used to inhibit the inflammatory responses and the preparation of the related compositions.

The present invention describes a method of inhibiting inflammatory response by using a lipopolysaccharide of Parabacteroides goldsteinii. The lipopolysaccharide of Parabacteroides goldsteinii can effectively inhibit the immune responses caused by pathogenic lipopolysaccharides in peripheral blood mononuclear cells, macrophages, and/or B cells, and then can be effectively used to inhibit the inflammatory responses and the preparation of the related compositions.

The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.

The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.

The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.

The invention provides compositions comprising bacterial strains for treating and preventing cancer.

The invention provides compositions comprising bacterial strains for treating and preventing cancer.

This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of vaccines. This invention also provides a method of treating a subject comprising administrating the above pharmaceutical composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of natural antibodies. This invention provides a composition comprising effective amount of glucan capable of enhancing host immunity. This invention also provides a composition comprising effective amount of glucan capable of enhancing the action of an agent in preventing tissue rejection.

Embodiments described herein relate to combinatorial compositions and uses thereof, for example, as vaccine adjuvant compositions, for enhancing immune response, for inducing differentiation of nave T cells to differentiate into IFN-γ-producing T cells, and for preventing and treating infections. The combinatorial composition comprises TLR and CLR agonists. The combinatorial composition comprises at least one TLR4 agonist and at least one Dectin-1 agonist, wherein the at least TLR4 agonist is monophosphoryl lipid A (MPLA) or glycopyranosyl lipid A (GLA), or the combinatorial composition comprises at least one TLR7/8 agonist and at least one Mincle agonist.